Anti-cancer agents in medicinal chemistry, vol.20, no.18, pp.2316-2323, 2020 (Journal Indexed in SCI Expanded)
Article / Article
Title of Journal :
Anti-cancer agents in medicinal chemistry
Ruxolitinib, multiple myeloma, autophagy, Interleukin-6, JAK, STAT, PATHWAY, EXPRESSION, SURVIVAL, GROWTH, DEATH
Background: Ruxolitinib is a selective JAK1/2 inhibitor approved by the FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise. In multiple myeloma which is a cancer of plasma cells, the Interleukin-6/JAK/STAT pathway is emerging as a therapeutic target since the overactivation of the pathway is associated with poor prognosis.